Table 3.
Cytotoxic activity of 1–15 against HL-60, A549, HSC-4, and HSC-2 cells a,b.
| Compound | IC50 (µM) | |||
|---|---|---|---|---|
| HL-60 | A549 | HSC-4 | HSC-2 | |
| 1 | 2.87 ± 0.15 | 2.54 ± 0.25 | 3.15 ± 0.43 | 0.96 ± 0.01 |
| 8 | >12 | 2.97 ± 0.06 | 11.04 ± 0.25 | 8.25 ± 0.20 |
| doxorubicin | ― | ― | 0.05 ± 0.01 | 0.11 ± 0.01 |
| etoposide | 0.40 ± 0.01 | 0.72 ± 0.03 | ― | ― |
| cisplatin | 1.33 ± 0.03 | 2.56 ± 0.05 | 1.88 ± 0.06 | 2.17 ± 0.06 |
a Data are represented as the mean value ± standard error of the mean (SEM) of three experiments performed in triplicate. b Compounds 2–7 and 9–15 were inactive against tumor cells (IC50 > 12 μM).